vTv Therapeutics Inc. Class A Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for VTVT, updated each market day.
VTVT AI Sentiment
AI predicts vTv Therapeutics Inc. Class A Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About vTv Therapeutics Inc. Class A Common Stock
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Sector
Exchange
Market Cap
$146,911,794
Cap Tier
Employees
26
Headquarters
HIGH POINT, NC
Listed Since
July 30, 2015
Website
VTVT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VTVT Volatility
vTv Therapeutics Inc. Class A Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
